Cornelia Englisch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Cornelia Englisch has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Cihan Ay
Medical University of Vienna
17 shared publications - Florian Moik
Division of Oncology, Department of Internal Medicine Medical University of Graz Graz Austria
7 shared publications - Ingrid Pabinger
Medical University of Vienna
7 shared publications Ingrid Pabinger
Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
6 shared publications- Stephan Nopp
Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
6 shared publications - Matthias Preusser
Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
5 shared publications
Latest Publications
- Open Access
Peripheral blood DNA methylation profile and immune checkpoint inhibitor response in cancer patients
- Open Access
- 9 May 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (4) , 106650
Clonal hematopoiesis and thrombosis risk—what are research and clinical gaps?
- 9 May 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (4) , 106650
Open AccessClonal hematopoiesis and thrombosis risk—what are research and clinical gaps?
- 2 September 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (12) , 1718-1728
Clonal Hematopoiesis and Cardiovascular Events in Patients with ESKD on Hemodialysis
Key Points: The prevalence of clonal hematopoiesis in patients with ESKD on hemodialysis was 7%. Clonal hematopoiesis was not associated with stroke, myocardial infarction, or venous thromboembolism. Clonal hematopoiesis was associated with vascular access thrombosis. Background: Patients with ESKD on hemodialysis are at high risk for cardiovascular complications. Clonal hematopoiesis (CH), defined as clonal expansion of hematopoietic stem cells due to acquired mutations, was shown to be associated with cardiovascular events, but this association was not yet assessed in patients with impaired kidney function. Methods: Our aim was to investigate the CH-associated mutation prevalence in patients with ESKD on hemodialysis included in the population-based prospective observational Vienna InVestigation of AtriaL Fibrillation and thromboembolism in hemoDIalysis (VIVALDI) study and to assess an association between CH and cardiovascular outcomes. Peripheral blood DNA samples collected at study inclusion were screened for CH-associated mutations. Results: Five hundred seventy patients were analyzed (median age, 66 years [interquartile range [IQR], 55–75]; 37.1% female). The median follow-up time was 39 months (IQR, 35–41). We detected 44 CH-associated variants in 40 patients (7%), most commonly in the gene DNMT3A (43%), TET2 (18%), and TP53 (18%). Patients with CH were older (75 [IQR, 68–80] versus 65 [IQR, 54–74] years, P < 0.001) and had longer cumulative dialysis time (4 [IQR, 1.0–4.0] versus 2 [IQR, 1.9–5.5] years, P = 0.02). CH was not associated with stroke (subdistribution hazard ratio [SHR], 0.25; 95% confidence interval [CI], 0.04 to 1.84), myocardial infarction (SHR, 0.90; 95% CI, 0.20 to 4.13), three-point major adverse cardiovascular events (SHR, 0.65; 95% CI, 0.33 to 1.28), or venous thromboembolism (SHR, 1.68; 95% CI, 0.35 to 8.12) risk. Patients with CH exhibited a higher risk of vascular access thrombosis (SHR, 2.47; 95% CI, 1.34 to 4.56) and patients with non- DNMT3A CH present with a higher all-cause mortality risk (hazard ratio, 1.71; 95% CI, 1.03 to 2.85). Conclusions: Seven percent of patients with ESKD on hemodialysis presented with CH. There was no association between CH and stroke, myocardial infarction, or venous thromboembolism. CH was associated with vascular access thrombosis.
- 2 September 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (12) , 1718-1728
Clonal Hematopoiesis and Cardiovascular Events in Patients with ESKD on Hemodialysis
Key Points: The prevalence of clonal hematopoiesis in patients with ESKD on hemodialysis was 7%. Clonal hematopoiesis was not associated with stroke, myocardial infarction, or venous thromboembolism. Clonal hematopoiesis was associated with vascular access thrombosis. Background: Patients with ESKD on hemodialysis are at high risk for cardiovascular complications. Clonal hematopoiesis (CH), defined as clonal expansion of hematopoietic stem cells due to acquired mutations, was shown to be associated with cardiovascular events, but this association was not yet assessed in patients with impaired kidney function. Methods: Our aim was to investigate the CH-associated mutation prevalence in patients with ESKD on hemodialysis included in the population-based prospective observational Vienna InVestigation of AtriaL Fibrillation and thromboembolism in hemoDIalysis (VIVALDI) study and to assess an association between CH and cardiovascular outcomes. Peripheral blood DNA samples collected at study inclusion were screened for CH-associated mutations. Results: Five hundred seventy patients were analyzed (median age, 66 years [interquartile range [IQR], 55–75]; 37.1% female). The median follow-up time was 39 months (IQR, 35–41). We detected 44 CH-associated variants in 40 patients (7%), most commonly in the gene DNMT3A (43%), TET2 (18%), and TP53 (18%). Patients with CH were older (75 [IQR, 68–80] versus 65 [IQR, 54–74] years, P < 0.001) and had longer cumulative dialysis time (4 [IQR, 1.0–4.0] versus 2 [IQR, 1.9–5.5] years, P = 0.02). CH was not associated with stroke (subdistribution hazard ratio [SHR], 0.25; 95% confidence interval [CI], 0.04 to 1.84), myocardial infarction (SHR, 0.90; 95% CI, 0.20 to 4.13), three-point major adverse cardiovascular events (SHR, 0.65; 95% CI, 0.33 to 1.28), or venous thromboembolism (SHR, 1.68; 95% CI, 0.35 to 8.12) risk. Patients with CH exhibited a higher risk of vascular access thrombosis (SHR, 2.47; 95% CI, 1.34 to 4.56) and patients with non- DNMT3A CH present with a higher all-cause mortality risk (hazard ratio, 1.71; 95% CI, 1.03 to 2.85). Conclusions: Seven percent of patients with ESKD on hemodialysis presented with CH. There was no association between CH and stroke, myocardial infarction, or venous thromboembolism. CH was associated with vascular access thrombosis.
- Open Access
- 8 July 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (13) , 3340-3349
Validation of risk assessment models for venous thromboembolism in patients with cancer receiving systemic therapies
Cancer increases the risk of venous thromboembolism (VTE). To identify patients with cancer at high VTE risk who might benefit from primary thromboprophylaxis, several risk assessment models (RAMs) have been developed. The evolution of anticancer treatment, including the implementation of targeted and immunotherapeutic agents, might affect VTE risk and risk prediction. Therefore, we aimed to evaluate the performance of 6 externally validated RAMs (Khorana score, PROTECHT, CONKO, COMPASS-CAT, CATScore, and EHR-CAT) in a prospective observational cohort study of patients with cancer initiating contemporary systemic anticancer therapies. Eight hundred six patients (49.5% female) with a median age of 61 years (interquartile range, 53-69) were included. The most common cancer types were lung (21.8%), breast (10.8%), and pancreatic (10.3%). Anticancer therapies initiated at study inclusion included chemotherapy (48.3%), a combination of chemotherapy and immune checkpoint inhibitor (ICI; 16.6%), ICI monotherapy (15.4%), and targeted agents (19.7%). During an observation period of 6 months, 91 patients experienced a VTE (cumulative incidence, 11.2%; 95% confidence interval [CI], 9.0-13.3). The discriminatory performance of the RAMs varied, with the best c-statistic seen with the CAT Score, whereas the COMPASS-CAT score showed the lowest area under the curve value (c-statistics: Khorana score, 0.53 [95% CI, 0.50-0.56]; PROTECHT, 0.58 [95% CI, 0.56-0.61]; CONKO, 0.54 [95% CI, 0.51-0.57]; COMPASS-CAT, 0.50 [95% CI, 0.47-0.53]; CAT Score, 0.65 [95% CI, 0.62-0.67]; EHR-CAT, 0.55 [95% CI, 0.52-0.57]). Overall, we observed a poor to modest discriminatory performance of the RAMs in our contemporary cohort of patients with cancer, with the CAT Score performing best among all evaluated scores.
- 8 July 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (13) , 3340-3349
Open AccessValidation of risk assessment models for venous thromboembolism in patients with cancer receiving systemic therapies
Cancer increases the risk of venous thromboembolism (VTE). To identify patients with cancer at high VTE risk who might benefit from primary thromboprophylaxis, several risk assessment models (RAMs) have been developed. The evolution of anticancer treatment, including the implementation of targeted and immunotherapeutic agents, might affect VTE risk and risk prediction. Therefore, we aimed to evaluate the performance of 6 externally validated RAMs (Khorana score, PROTECHT, CONKO, COMPASS-CAT, CATScore, and EHR-CAT) in a prospective observational cohort study of patients with cancer initiating contemporary systemic anticancer therapies. Eight hundred six patients (49.5% female) with a median age of 61 years (interquartile range, 53-69) were included. The most common cancer types were lung (21.8%), breast (10.8%), and pancreatic (10.3%). Anticancer therapies initiated at study inclusion included chemotherapy (48.3%), a combination of chemotherapy and immune checkpoint inhibitor (ICI; 16.6%), ICI monotherapy (15.4%), and targeted agents (19.7%). During an observation period of 6 months, 91 patients experienced a VTE (cumulative incidence, 11.2%; 95% confidence interval [CI], 9.0-13.3). The discriminatory performance of the RAMs varied, with the best c-statistic seen with the CAT Score, whereas the COMPASS-CAT score showed the lowest area under the curve value (c-statistics: Khorana score, 0.53 [95% CI, 0.50-0.56]; PROTECHT, 0.58 [95% CI, 0.56-0.61]; CONKO, 0.54 [95% CI, 0.51-0.57]; COMPASS-CAT, 0.50 [95% CI, 0.47-0.53]; CAT Score, 0.65 [95% CI, 0.62-0.67]; EHR-CAT, 0.55 [95% CI, 0.52-0.57]). Overall, we observed a poor to modest discriminatory performance of the RAMs in our contemporary cohort of patients with cancer, with the CAT Score performing best among all evaluated scores.
- Open Access
- 9 May 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (4) , 102882
Clonal hematopoiesis in patients with cancer and its association with risk of thrombosis and prognosis of disease
- 9 May 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (4) , 102882
Open AccessClonal hematopoiesis in patients with cancer and its association with risk of thrombosis and prognosis of disease
- Open Access
- 7 April 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (6) , 1049-1060
Clonal Hematopoiesis and Thrombosis
Clonal hematopoiesis (CH) has been the focus of many research efforts in the last years and has emerged as a risk modifier for cardiovascular disease morbidity and mortality. While substantial evidence has accumulated regarding its impact on arterial system diseases, the connection with venous thrombosis has only recently been explored. Both clinical and preclinical evidence suggest that the magnitude and mechanism underlying the association of CH with cardiovascular events vary depending on the specific mutated gene involved, indicating a causal link between CH and thrombosis development, not only in the arterial system, particularly in the context of atherosclerosis, but also in venous thrombosis. Although this growing body of knowledge has driven translational research and provided insights for improving clinical management, several questions remain unanswered. This review aims to summarize the available evidence on the link between CH and thrombosis, while highlighting the gaps that need to be addressed in future research.
- 7 April 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (6) , 1049-1060
Open AccessClonal Hematopoiesis and Thrombosis
Clonal hematopoiesis (CH) has been the focus of many research efforts in the last years and has emerged as a risk modifier for cardiovascular disease morbidity and mortality. While substantial evidence has accumulated regarding its impact on arterial system diseases, the connection with venous thrombosis has only recently been explored. Both clinical and preclinical evidence suggest that the magnitude and mechanism underlying the association of CH with cardiovascular events vary depending on the specific mutated gene involved, indicating a causal link between CH and thrombosis development, not only in the arterial system, particularly in the context of atherosclerosis, but also in venous thrombosis. Although this growing body of knowledge has driven translational research and provided insights for improving clinical management, several questions remain unanswered. This review aims to summarize the available evidence on the link between CH and thrombosis, while highlighting the gaps that need to be addressed in future research.
- Open Access
- 14 January 2025
- Published by Elsevier in JACC: Cardiooncology
- Vol. 7 (2) , 141-152
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients
- 14 January 2025
- Published by Elsevier in JACC: Cardiooncology
- Vol. 7 (2) , 141-152
Open AccessGrowth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients
- Open Access
- 24 December 2024
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (1) , 102664
Risk assessment and prevention of cancer-associated venous thromboembolism in ambulatory patients with solid malignancies
- 24 December 2024
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (1) , 102664
Open AccessRisk assessment and prevention of cancer-associated venous thromboembolism in ambulatory patients with solid malignancies